Maze Therapeutics
MAZE
143 hedge funds and large institutions have $2B invested in Maze Therapeutics in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 46 increasing their positions, 20 reducing their positions, and 8 closing their positions.
613% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 8
130% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 20
80% more capital invested
Capital invested by funds: $1.11B → $2B (+$889M)
52% more funds holding
Funds holding: 94 → 143 (+49)
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
2.52% more ownership
Funds ownership: 97.99% → 100.51% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$82.2M |
| 2 |
BlackRock
New York
|
+$33.4M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$30.5M |
| 4 |
CP
Caligan Partners
New York
|
+$18.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$55M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$40.3M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$35.2M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.53M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.06M |
MAZE Hedge Fund Activity: Q4 2025 in Review
143 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q4 2025, worth a combined $2B — up 80% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new MAZE positions and 8 closed out — a net gain of 49 holders — while 46 added to existing stakes and 20 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $82.2M. The largest seller was TRV GP IV, cutting an estimated $55M.
- 143 institutional investors held Maze Therapeutics (MAZE) as of Q4 2025, up from 94 in Q3 2025.
- Funds reported $2B of Maze Therapeutics stock for Q4 2025, up 80% quarter-over-quarter.
- 57 funds opened new Maze Therapeutics positions in Q4 2025 and 8 closed out, a net change of +49 holders.
- The largest Maze Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $82.2M added.
- The largest Maze Therapeutics seller in Q4 2025 was TRV GP IV, an estimated $55M sold.
Based on aggregated 13F filings for Q4 2025.